ArticleBMC veterinary research2026
MicroRNA signatures of equine asthma phenotypes in serum and bronchoalveolar lavage fluid.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEquine asthma (EA) is a highly prevalent, chronic, inflammatory disease of the lower airways ranging from mild-to-moderate to severe clinical presentations. Diagnosis currently relies on bronchoalveolar lavage fluid (BALF) cytology, an invasive method associated with interobserver variability, which highlights the need for more reproducible approaches. MicroRNAs (miRNAs) are small noncoding RNAs involved in gene regulation. They are stable and readily detectable in body fluids and have shown promising results as biomarkers in human asthma. The aim of this pilot study was to characterize miRNA expression profiles in BALF and serum from horses with distinct EA phenotypes to evaluate their biomarker potential and explore their putative involvement in disease pathogenesis.
resultsA total of 43 horses were included and classified as either EA (n = 32) or controls (n = 11), based on clinical examination and BALF cytology. The EA horses were further divided into three phenotypes based on BALF inflammatory cell composition: neutrophilic asthma (n = 10), mastocytic asthma (n = 15), and mixed asthma (n = 7). RNA was isolated from both serum and BALF samples and analyzed by quantitative real-time PCR (qPCR) targeting 103 miRNAs linked to asthma and pulmonary inflammation in humans. Differential miRNA expression was analyzed across EA phenotypes. The most significantly differentially expressed miRNAs were used for hypothesis-generation by in silico target prediction and pathway enrichment exploratory analyses. Horses with mixed EA had significantly lower levels of eca-miR-125a-3p and eca-miR-125b-5p in BALF compared to controls. Additionally, eca-miR-146a-5p expression was significantly increased in BALF from horses with neutrophilic EA compared to mastocytic EA. For serum, none of the miRNAs showed significant differential expression within the EA phenotypes. Target and pathway enrichment analyses for eca-miR-146a-5p identified immune-relevant pathways supporting its possible involvement in inflammatory processes associated with asthma.
conclusionsThis study identified three promising candidates, eca-miR-125a-3p, eca-miR-125b-5p, and eca-miR-146a-5p, as potential biomarkers in BALF associated with different EA phenotypes. These miRNAs are interesting candidates for further validation in an independent cohort before they can be used in diagnostics.
Indexed as
Identifiers
42881456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.